

PC
10/29/88
1
33. (AMENDED) A method of treating in a human [in whom it is desired to induce long term immunological unresponsiveness to a specific] a disorder mediated by an immune reaction to an antigen possessed by said human and presented to CD4+ T-cells within said human, ^{said} ~~which~~ method [consists essentially of] ^{comprising} ~~comprises~~ administering to said human an amount of a non-depleting anti-CD4 monoclonal antibody and a non-depleting anti-CD8 monoclonal antibody sufficient to induce [said] long term specific immunological unresponsiveness [within said human] to said antigen thereby effecting said treatment.

Cancel claims 34-36 without prejudice.

Amend claim 37 as follows:

D2
37. (AMENDED) A method of treating in a human [in whom it is desired to induce long term immunological unresponsiveness to a specific] a disorder mediated by an immune reaction to an antigen possessed by said human and presented to CD4+ T-cells within said human [selected from the group consisting of transplantation antigens and immunoglobulins], ^{said} ~~which~~ method

2
1
2
[consists essentially of] ~~comprises~~ ^{comprising} administering to said human an amount of a non-depleting anti-CD4 monoclonal antibody sufficient to induce [said] long term specific immunological unresponsiveness [within said human] to said antigen thereby effecting said treatment.

Cancel claims 38-40 without prejudice.

Amend claim 41 as follows:

10/19/98
24
41. (AMENDED) A method of treating [inducing long term immunological unresponsiveness to a specific autoantigen], in a human [in need of said induction], a disorder mediated by an immune reaction to a self antigen, ^{said} ~~which method comprises~~ ^{comprising} administering to [said] a human in need of said treatment an amount of a non-depleting anti-CD4 monoclonal antibody[, or antibody binding site-containing fragment thereof,] sufficient to induce [said] long term specific immunological unresponsiveness ^{self} to said antigen thereby effecting said treatment.

Add the following new claims:

PL
10/24/88

8
44. The method according to claim ~~41~~⁴¹ wherein said method comprises administering an amount of an antibody-binding site containing fragment of a non-depleting anti-CD4 monoclonal antibody sufficient to effect said treatment.

D4

9
46. The method of claim ~~42~~⁵ wherein said immunosuppressive agent is an immunosuppressive antibody, a steroid, cyclosporin or anti-lymphocyte globulin.

P

2
47. The method of claim ~~33~~¹ or ~~37~~ further comprising administering to said human a therapeutically effective amount of one or more immunosuppressive agents.

3
48. The method of claim ~~47~~² wherein said immunosuppressive agent is an immunosuppressive antibody, a steroid, cyclosporin or anti-lymphocyte globulin.--